<p>Relapse after allogeneic hematopoietic stem cell transplantation (HSCT) is characterized by poor outcomes and novel therapeutic options are urgently needed. Immune checkpoint blockade using CTLA-4 and PD-1 blocking antibodies are a potential concept for reinstating a dormant graft-versus-leukemia (Gvl) effect. This study investigated transcriptomic changes in biopsies obtained from patients who received immune checkpoint blockade for relapsed hematologic malignancy post-HSCT and elucidated transcriptional programs associated with successful reinvigoration of GvL. Differential gene expression analysis showed evidence of increased T cell infiltration in biopsies of responders to ipilimumab treatment and demonstrated shared gene programs between GvL and GvHD.</p>

Immune Checkpoint Blockade for Relapsed Hematologic Malignancy Post-HSCT

CTLA-4 Antigen study on dbGaP (36 participants)

Immune Checkpoint Blockade for Relapsed Hematologic Malignancy Post-HSCT

Description

Applying For Access

Summary